News: OncoSil Medical appoints Daniel Kenny a director

OncoSil Medical (ASX:OSL) has appointed its incoming chief executive officer Daniel Kenny as a director of the company.

Kenny, who has more than 30 years’ experience in the global pharmaceutical industry, will commence as the company’s chief executive officer from 5 January 2015.

He will execute growth plans as the company drives towards registration of its OncoSil™ localised radiation therapy medical device for treatment of pancreatic cancer.

Dr Neil Frazer has resigned as a director but will remain with the company as its chief medical officer.

The company continues to advance the clinical development pathway for the OncoSil™ device as a new and commercially available option for the treatment of pancreatic cancer, and then marketing the product on a global basis.

It recently commenced a Pivotal Trial that will enrol 150 patients across 20 trial sites.

This will compare patients receiving standard-of-care (for inoperable pancreatic cancer this includes chemotherapy treatment) with patients receiving standard-of-care plus OncoSil treatment, in a randomised and controlled fashion.

The Australian trial is expected to take 12-18 months to evaluate patients and determine their progress.

A key goal of the trial is also to have results published in a prestigious medical journal, with a view to influencing the standard-of-care (the current accepted best practice treatment) provided to pancreatic cancer patients globally.

Positive, data generated by the Trial may facilitate the commercialisation of OncoSil, including in the US, which is the world's largest health care market.

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.